All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On April 21, 2020, the acute myeloid leukemia (AML) World Awareness Day will enable the community to unite, share knowledge, and raise awareness of the advances in the prevention, management, and treatment of AML. To find out how you can participate in AML World Awareness Day, visit www.know-aml.com.
Despite advances in the field of targeted therapies, hematopoietic stem cell transplantation (HSCT) is still an important curative option for a number of hematological and non-hematological disorders.1 Over the last years, changes such as the use of cord blood (CB) cells or haploidentical donors as stem cell sources, conditioning regimens, and graft-versus-host disease prophylaxis have increased the accessibility to HSCT,1 augmenting the number of global annual HSCT.2
In a paper, published in Biology of Blood and Marrow Transplantation, David Kliman and colleagues reported the outcome of long-term survivors who underwent HSCT from 2002–2011. Data were obtained from the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) and compared with survivors transplanted between 1992–2001 and with the age-matched general population.3
Compared with 2-year allo-HSCT survivors from 1992─2001, the 2002─2011 cohort presented different characteristics, reported in Table 1.
Table 1. Patient and transplant characteristics of 2-year allo-HSCT survivors by time periods
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; CML, chronic myeloid leukemia; MDS, myelodysplastic syndromes; NHL, non-Hodgkin lymphoma; PB, peripheral blood |
|||
Characteristic |
1992─2001 N = 1038 |
2002─2011 N = 1562 |
p value |
---|---|---|---|
Median age (years) |
33 (0.4–68) |
38 (0.3–71.5) |
< 0.001 |
Hematopoietic cell source BM PB CB Other |
716 (69%) 295 (28%) 19 (2%) 8 (1%) |
330 (21%) 1,071 (69%) 160 (10%) 1 (0%) |
< 0.001 |
Conditioning intensity Myeloablative Reduced intensity |
1,006 (97%) 32 (3%) |
1,151 (74%) 411 (26%) |
< 0.001 |
Indication for transplant ALL AML CML MDS NHL |
242 (23%) 326 (31%) 334 (32%) 51 (5%) 85 (8%) |
400 (26%) 755 (48%) 124 (8%) 127 (8%) 156 (10%) |
< 0.001 |
Donor relation HLA-identical sibling Haploidentical Other related Syngeneic Unrelated |
753 (73%) 3 (0.3%) 81 (8%) 11 (1%) 190 (18%) |
810 (52%) 11 (1%) 35 (2%) 18 (1%) 688 (44%) |
< 0.001 |
Despite the different characteristics, such as transplant age (with an increase from 11% to 21% in patients transplanted at ages 50─59, and from 1% to 7% in patients transplanted over 60 years), cell source, and donors, the 10-year OS was similar between the two cohorts: 78.4% vs 80.3% in the 1992─2001 vs the 2002─2011 cohort, respectively. Favorable factors associated with OS were age < 16 years and transplantation for CML, whereas adverse factors were represented by peripheral blood (PB) stem cell source, transplantation for MDS, male recipient, poor risk disease, and age > 45 years. Hazard ratio (HR), 95% confidence interval (CI), and p values for each variable are reported in Table 2.
Table 2. Risk factors for OS in 2-year allo-HSCT survivors3
CI, confidence interval; CML, chronic myeloid leukemia; HR, hazard ratio; MDS, myelodysplastic syndromes |
|||
Variable |
HR |
95% CI |
p value |
---|---|---|---|
Age < 16 years |
0.58 |
0.43─0.79 |
0.001 |
Transplantation for CML |
0.69
|
0.54─0.90 |
0.005 |
PB stem cell source |
1.25 |
1.02─1.54 |
0.03 |
Transplantation for MDS |
1.44 |
1.02─2.04 |
0.04 |
Male recipient |
1.44 |
1.19─1.74 |
< 0.001 |
Poor risk disease |
1.57 |
1.30─1.90 |
< 0.001 |
Age > 45 years |
1.63 |
1.30─1.90 |
< 0.001 |
The characteristics of the 2-year auto-HSCT survivors from the 2002─2011 cohort were compared with the 1992─2001 cohort and are reported in Table 3. An increase in median age at transplant (with a greater proportion of patients, 37% vs 16%, transplanted over 60 years in the 2002─2011 cohort vs the 1992─2001 cohort) and a decrease in the use of BM as stem cell source were observed.
Table 3. Patient and transplant characteristics of 2-year auto-HSCT survivors by time period3
BM, bone marrow; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PB peripheral blood |
|||
Characteristic |
1992─2001 N = 1630 |
2002─2011 N = 3822 |
p value |
---|---|---|---|
Median age, years (range) |
49 (6─75) |
56 (4.4─79) |
< 0.001 |
Hematopoietic cell source BM PB BM & PB |
118 (7%) 1,452 (89%) 60 (4%) |
17 (0%) 3,787 (99%) 78 (0%) |
< 0.001 |
Indication for transplant HL MM NHL |
236 (14%) 600 (37%) 794 (49%) |
379 (10%) 1,981 (52%) 1,462 (38%) |
< 0.001 |
Despite these differences, by 10-year post auto-HSCT,
Adverse risk factors for OS were
The relative survival ratio was close to the age-matched population but still significantly lower (89–96%), with a better relative survival for patients with lymphoma (91–97%) compared with MM (88–96%).
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox